Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28


A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer.

Ruzzolini J, Laurenzana A, Andreucci E, Peppicelli S, Bianchini F, Carta F, Supuran CT, Romanelli MN, Nediani C, Calorini L.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):391-397. doi: 10.1080/14756366.2019.1706090.


Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells.

Peppicelli S, Ruzzolini J, Andreucci E, Bianchini F, Kontos F, Yamada T, Ferrone S, Calorini L.

Cancers (Basel). 2019 Aug 26;11(9). pii: E1249. doi: 10.3390/cancers11091249.


Anoikis Resistance as a Further Trait of Acidic-Adapted Melanoma Cells.

Peppicelli S, Ruzzolini J, Bianchini F, Andreucci E, Nediani C, Laurenzana A, Margheri F, Fibbi G, Calorini L.

J Oncol. 2019 Jun 2;2019:8340926. doi: 10.1155/2019/8340926. eCollection 2019.


Integrin-targeted AmpRGD sunitinib liposomes as integrated antiangiogenic tools.

Bianchini F, De Santis A, Portioli E, Russo Krauss I, Battistini L, Curti C, Peppicelli S, Calorini L, D'Errico G, Zanardi F, Sartori A.

Nanomedicine. 2019 Jun;18:135-145. doi: 10.1016/j.nano.2019.02.015. Epub 2019 Mar 6.


Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma.

Bianchini F, Portioli E, Ferlenghi F, Vacondio F, Andreucci E, Biagioni A, Ruzzolini J, Peppicelli S, Lulli M, Calorini L, Battistini L, Zanardi F, Sartori A.

Cancer Lett. 2019 Apr 1;446:25-37. doi: 10.1016/j.canlet.2018.12.021. Epub 2019 Jan 11.


EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.

Laurenzana A, Margheri F, Biagioni A, Chillà A, Pimpinelli N, Ruzzolini J, Peppicelli S, Andreucci E, Calorini L, Serratì S, Del Rosso M, Fibbi G.

EBioMedicine. 2019 Jan;39:194-206. doi: 10.1016/j.ebiom.2018.12.024. Epub 2019 Jan 2.


Oleuropein, the Main Polyphenol of Olea europaea Leaf Extract, Has an Anti-Cancer Effect on Human BRAF Melanoma Cells and Potentiates the Cytotoxicity of Current Chemotherapies.

Ruzzolini J, Peppicelli S, Andreucci E, Bianchini F, Scardigli A, Romani A, la Marca G, Nediani C, Calorini L.

Nutrients. 2018 Dec 8;10(12). pii: E1950. doi: 10.3390/nu10121950.


SOX2 as a novel contributor of oxidative metabolism in melanoma cells.

Andreucci E, Pietrobono S, Peppicelli S, Ruzzolini J, Bianchini F, Biagioni A, Stecca B, Calorini L.

Cell Commun Signal. 2018 Nov 22;16(1):87. doi: 10.1186/s12964-018-0297-z.


The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy.

Andreucci E, Ruzzolini J, Peppicelli S, Bianchini F, Laurenzana A, Carta F, Supuran CT, Calorini L.

J Enzyme Inhib Med Chem. 2019 Dec;34(1):117-123. doi: 10.1080/14756366.2018.1532419.


Gold Nanoparticles Functionalized with RGD-Semipeptides: A Simple yet Highly Effective Targeting System for αV β3 Integrins.

Maggi V, Bianchini F, Portioli E, Peppicelli S, Lulli M, Bani D, Sole RD, Zanardi F, Sartori A, Fiammengo R.

Chemistry. 2018 Aug 14;24(46):12093-12100. doi: 10.1002/chem.201801823. Epub 2018 Jul 16.


Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis.

Andreucci E, Peppicelli S, Carta F, Brisotto G, Biscontin E, Ruzzolini J, Bianchini F, Biagioni A, Supuran CT, Calorini L.

J Mol Med (Berl). 2017 Dec;95(12):1341-1353. doi: 10.1007/s00109-017-1590-9. Epub 2017 Sep 19.


Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.

Ruzzolini J, Peppicelli S, Andreucci E, Bianchini F, Margheri F, Laurenzana A, Fibbi G, Pimpinelli N, Calorini L.

Cancer Lett. 2017 Nov 1;408:43-54. doi: 10.1016/j.canlet.2017.08.010. Epub 2017 Aug 18.


uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells.

Laurenzana A, Chillà A, Luciani C, Peppicelli S, Biagioni A, Bianchini F, Tenedini E, Torre E, Mocali A, Calorini L, Margheri F, Fibbi G, Del Rosso M.

Int J Cancer. 2017 Sep 15;141(6):1190-1200. doi: 10.1002/ijc.30817. Epub 2017 Jun 21.


Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.

Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, Mercatanti A, Comelli L, Gurrieri S, Wu LW, Ope O, Flaherty K, Boland GM, Hammond MR, Kwong L, Chiariello M, Stecca B, Zhang G, Salvetti A, Angeloni D, Pitto L, Calorini L, Chiorino G, Pellegrini M, Herlyn M, Osman I, Poliseno L.

Oncotarget. 2017 Apr 11;8(15):25395-25417. doi: 10.18632/oncotarget.15915.


The acidic microenvironment as a possible niche of dormant tumor cells.

Peppicelli S, Andreucci E, Ruzzolini J, Laurenzana A, Margheri F, Fibbi G, Del Rosso M, Bianchini F, Calorini L.

Cell Mol Life Sci. 2017 Aug;74(15):2761-2771. doi: 10.1007/s00018-017-2496-y. Epub 2017 Mar 22. Review.


Chronic Resveratrol Treatment Inhibits MRC5 Fibroblast SASP-Related Protumoral Effects on Melanoma Cells.

Menicacci B, Laurenzana A, Chillà A, Margheri F, Peppicelli S, Tanganelli E, Fibbi G, Giovannelli L, Del Rosso M, Mocali A.

J Gerontol A Biol Sci Med Sci. 2017 Sep 1;72(9):1187-1195. doi: 10.1093/gerona/glw336.


Triazole RGD antagonist reverts TGFβ1-induced endothelial-to-mesenchymal transition in endothelial precursor cells.

Bianchini F, Peppicelli S, Fabbrizzi P, Biagioni A, Mazzanti B, Menchi G, Calorini L, Pupi A, Trabocchi A.

Mol Cell Biochem. 2017 Jan;424(1-2):99-110. doi: 10.1007/s11010-016-2847-2. Epub 2016 Oct 19.


Metformin is also effective on lactic acidosis-exposed melanoma cells switched to oxidative phosphorylation.

Peppicelli S, Toti A, Giannoni E, Bianchini F, Margheri F, Del Rosso M, Calorini L.

Cell Cycle. 2016 Jul 17;15(14):1908-18. doi: 10.1080/15384101.2016.1191706. Epub 2016 Jun 6.


Extracellular acidity strengthens mesenchymal stem cells to promote melanoma progression.

Peppicelli S, Bianchini F, Toti A, Laurenzana A, Fibbi G, Calorini L.

Cell Cycle. 2015;14(19):3088-100. doi: 10.1080/15384101.2015.1078032.


Metabolic reprogramming as a continuous changing behavior of tumor cells.

Peppicelli S, Bianchini F, Calorini L.

Tumour Biol. 2015 Aug;36(8):5759-62. doi: 10.1007/s13277-015-3762-y. Epub 2015 Jul 10.


Supplemental Content

Loading ...
Support Center